Philips has released a package of enhancements and new system configurations for its ultrasound portfolio. The upgrades, known collectively as Vision 2005, include new capabilities for the company’s latest radiology and cardiology platforms.
Philips has released a package of enhancements and new system configurations for its ultrasound portfolio. The upgrades, known collectively as Vision 2005, include new capabilities for the company's latest radiology and cardiology platforms.
Highlights include new pediatric cardiology capabilities and enhanced vascular capabilities on the iE33 (cardiology) system, cardiology capabilities and photo-quality 3D fetal imaging on the iU22 (radiology) system, and oncart and offcart upgrades to QLAB Quantification Software on both platforms.
Philips' iE33 (intelligent echo) system and iU22 (intelligent ultrasound) system support traditional 2D as well as 3D and 4D visualization. They use advanced transducer technology (xMATRIX), crystals (PureWave), user-centered ergonomics, and volumetric quantification. Several enhancements build on these core technologies.
On the iE33, 3DQ Advanced software is used to measure the contractility of the heart to help determine which patients are the best candidates for cardiac resynchronization therapy (CRT). Vision 2005 introduces 3D synchronicity indices that can quantify cardiac dyssynchrony and, thereby, standardize 3D evaluation for CRT. The pediatric cardiology package includes a new multiplanar transesophegeal echo transducer optimized for use during pediatric surgery.
On the iU22, Vision 2005 provides faster volume rates and better 4D image quality by incorporating Philips' SonoCT compound imaging. The X3-1 xMATRIX array transducer enables real-time volume-rendered imaging for general viewing as well as cardiac applications. Other enhancements include the ability to measure intima media thickness, an indicator of early atherosclerosis.
The 3D Viewer allows the review and display of 3D data sets and multiplanar reconstructions similar to those used in MR and CT. Analysis tools allow the review of contrast loops and creation of microvascular imaging files that visualize blood flow in extremely small vessels. Cardiac quantification of 3D data sets and strain quantification are also available.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.